PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10253869

Controlled substances system change provides increased accountability.

R A Proksch·A N Riley
View original source ↗Export metadata ↓

Abstract

The distribution and control systems for controlled substances were evaluated. A mail survey of other hospitals was conducted to obtain samples of control substance systems and the associated procedures. From these samples of existing programs and previous experiences with the current program, a system was designed to meet the needs of an 800-bed hospital with a decentralized pharmacy distribution system. The new distribution and control system completely replaced the prior system. Therefore, new forms and procedures were generated. The total system was implemented in a stepwise procedure in two-week increments over approximately 14 weeks until the entire hospital was converted. The new system has increased control as well as identified workload, inventory utilization, and problem areas.

Explore related subjects

Drug and Narcotic ControlForms and Records ControlHospital Bed Capacity, 500 and overHospital RecordsMarylandMedication Systems, HospitalOffice ManagementRecordsTime FactorsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R A Proksch, A N Riley. 1982. Controlled substances system change provides increased accountability.. https://pubmed.ncbi.nlm.nih.gov/10253869/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Clarification of registration requirements for individual practitioners. Final rule.

The Drug Enforcement Administration (DEA) is amending its registration regulations to make it clear that when an individual practitioner practices in more than one State, he or she must obtain a separate DEA registration for each State. This amendment will make it easier for practitioners to understand the requirements of the Controlled Substances Act and its implementing regulations.

Drug and Narcotic Control↗
PubMed2006

The legal status of medical marijuana.

OBJECTIVE: To review the legal status of medical marijuana in the US. DATA SOURCES: Relevant publications were located using LexisNexis (1982-October 2006), WestLaw (1996-October 2006), BNA Health Law Reporter (1996-October 2006), MEDLINE (1996-October 2006), EMBASE (1980-October 2006), International Pharmaceutical Abstracts (1970-October 2006), and an Internet search targeting government sites using the key words medical marijuana. STUDY SELECTION AND DATA EXTRACTION: Federal and state medical marijuana laws were examined. Relevant cannabinoid-based drug products were reviewed. Federal and State Supreme Court and Appeal level cases involving medical marijuana were evaluated. DATA SYNTHESIS: Marijuana is regulated as a Schedule I controlled substance and its use is prohibited under federal law. Dronabinol and nabilone are synthetic cannabinoids approved by the Food and Drug Administration and Sativex is a cannabis-based extract being evaluated in Phase III trials. The federal government sponsors a single patient compassionate use Investigational New Drug Application program providing medical marijuana for a small number of patients. Eleven states permit marijuana use for medical purposes and one state provides a defense of medical necessity. Employers do not have to provide workplace accommodations for employees using medical marijuana and can terminate them at will. Healthcare providers have First Amendment constitutional protections that allow them to discuss marijuana with patients. CONCLUSIONS: Until the Supreme Court rules directly on the constitutionality of state medical marijuana laws, a conflict remains. Marijuana use remains illegal under federal law and states assume their medical marijuana laws to be constitutional.

Drug and Narcotic Control↗